PubMed Health⌕ Search

PubMed · 9438823

A computational fluid dynamic study of hawkmoth hovering

Abstract

A computational fluid dynamic (CFD) modelling approach is used to study the unsteady aerodynamics of the flapping wing of a hovering hawkmoth. We use the geometry of a Manduca sexta-based robotic wing to define the shape of a three-dimensional 'virtual' wing model and 'hover' this wing, mimicking accurately the three-dimensional movements of the wing of a hovering hawkmoth. Our CFD analysis has established an overall understanding of the viscous and unsteady flow around the flapping wing and of the time course of instantaneous force production, which reveals that hovering flight is dominated by the unsteady aerodynamics of both the instantaneous dynamics and also the past history of the wing. A coherent leading-edge vortex with axial flow was detected during translational motions of both the up- and downstrokes. The attached leading-edge vortex causes a negative pressure region and, hence, is responsible for enhancing lift production. The axial flow, which is derived from the spanwise pressure gradient, stabilises the vortex and gives it a characteristic spiral conical shape. The leading-edge vortex created during previous translational motion remains attached during the rotational motions of pronation and supination. This vortex, however, is substantially deformed due to coupling between the translational and rotational motions, develops into a complex structure, and is eventually shed before the subsequent translational motion. Estimation of the forces during one complete flapping cycle shows that lift is produced mainly during the downstroke and the latter half of the upstroke, with little force generated during pronation and supination. The stroke plane angle that satisfies the horizontal force balance of hovering is 23.6 degrees , which shows excellent agreement with observed angles of approximately 20-25 degrees . The time-averaged vertical force is 40 % greater than that needed to support the weight of the hawkmoth.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Liu, C Ellington, K Kawachi, c. 1998. A computational fluid dynamic study of hawkmoth hovering. https://doi.org/10.1242/jeb.201.4.461

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗